Immunic AG

The article highlights the Multiple Sclerosis (MS) market, focusing on companies, treatments, and market trends. It covers MS as a chronic autoimmune disease affecting the CNS, current and emerging therapies, market size growth expectations by 2034, and key companies like Novartis, Biogen, and Hoffmann-La Roche. It also mentions recent study results and the importance of understanding MS epidemiology, treatment algorithms, and unmet medical needs.

The Multiple Sclerosis (MS) market is projected to grow significantly by 2034, with key players like Novartis, Biogen, and Hoffmann-La Roche leading in treatment development. MS, a chronic autoimmune disease affecting the CNS, lacks a cure but treatments aim to manage symptoms and slow progression. Emerging therapies and ongoing studies highlight advancements in MS care.

Immunic AG highlighted 2024 achievements, including progress in Phase 2 CALLIPER and Phase 3 ENSURE trials for vidofludimus calcium in multiple sclerosis, expecting top-line data by April 2025. Strengthened leadership and secured $240M in funding, extending cash runway to Q3 2025. Also advanced IMU-856 for gastrointestinal disorders.

The article highlights the Multiple Sclerosis (MS) market, focusing on companies, treatments, and market trends. It covers MS as a chronic autoimmune disease affecting the CNS, current and emerging therapies, market size growth expected by 2034, and key companies like Novartis, Biogen, and Hoffmann-La Roche. It also mentions recent studies and the importance of understanding MS epidemiology, treatment algorithms, and unmet medical needs for future market opportunities.

Immunic AG highlighted 2024 achievements, including progress in Phase 2 CALLIPER and Phase 3 ENSURE trials for vidofludimus calcium in multiple sclerosis, expecting top-line data in April. Strengthened leadership and secured $80M in a private placement. Published IMU-856 trial results in The Lancet, showing potential in celiac disease treatment.